CalciMedica announced alignment with the FDA on key aspects of its Phase 2b trial for Auxora in acute pancreatitis, including the primary endpoint (new-onset severe respiratory failure) and a patient enrichment strategy using LDH. This clarity from the FDA significantly de-risks the clinical development pathway for Auxora, providing a defined framework for its potential registration program.
CalciMedica has secured crucial alignment with the FDA regarding the design of its Phase 2b trial for Auxora in acute pancreatitis. This includes agreement on new-onset severe respiratory failure as the primary endpoint and a biomarker-based patient enrichment strategy using LDH, which is expected to identify patients at higher risk of severe disease. This development is highly positive for CalciMedica as it provides a clear, de-risked path forward for its lead therapeutic candidate in a disease with no approved treatments. For traders, this reduces regulatory uncertainty and could lead to increased investor confidence in CALC's long-term prospects, although short-term price action will depend on broader market sentiment and the successful execution of the trial.